Pavle Repovic

Pavle Repovic

Neurology

1600 East Jefferson Street
A Level
Seattle, WA 98122

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 46 publications

Interleukin 6 Receptor Blockade for Relapse Prevention in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Interleukin 6 Receptor Blockade for Relapse Prevention in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Journal: JAMA neurology

Published: July 13, 2026

Diminishing returns of disease-modifying treatment in older participants of multiple sclerosis clinical trials.

Diminishing returns of disease-modifying treatment in older participants of multiple sclerosis clinical trials.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: March 20, 2026

Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial.

Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial.

Journal: Neurology

Published: December 15, 2025

Breaking the PROMISE: poor association between brain volume loss and clinical disability worsening over 2 years of follow-up in primary progressive multiple sclerosis.

Breaking the PROMISE: poor association between brain volume loss and clinical disability worsening over 2 years of follow-up in primary progressive multiple sclerosis.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: November 04, 2025

Extended window of relapse recovery in RRMS: an analysis of the DECIDE dataset.

Extended window of relapse recovery in RRMS: an analysis of the DECIDE dataset.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: May 13, 2025

Cognitive test performance and disease progression in primary and secondary progressive MS: An analysis of the SPRINT-MS study.

Cognitive test performance and disease progression in primary and secondary progressive MS: An analysis of the SPRINT-MS study.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: May 08, 2025

Utility of Progression Independent of Relapse Activity as a Trial Outcome in Relapsing-Remitting Multiple Sclerosis.

Utility of Progression Independent of Relapse Activity as a Trial Outcome in Relapsing-Remitting Multiple Sclerosis.

Journal: Neurology

Published: February 17, 2025

Measuring cognitive change in secondary progressive MS: an analysis of the ASCEND cognition substudy.

Measuring cognitive change in secondary progressive MS: an analysis of the ASCEND cognition substudy.

Journal: Journal of neurology

Published: January 27, 2025

Selecting Informative Patients for Phase 2 Progressive Trials in MS: Design Considerations for Phase 2 Clinical Trials in Progressive MS.

Selecting Informative Patients for Phase 2 Progressive Trials in MS: Design Considerations for Phase 2 Clinical Trials in Progressive MS.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: September 09, 2024

People with multiple sclerosis help design a tool to measure physical functioning and how it affects their daily lives: a plain language summary.

People with multiple sclerosis help design a tool to measure physical functioning and how it affects their daily lives: a plain language summary.

Journal: Neurodegenerative disease management

Published: July 26, 2024

Multi-Omic characterization of the effects of Ocrelizumab in patients with relapsing-remitting multiple sclerosis.

Multi-Omic characterization of the effects of Ocrelizumab in patients with relapsing-remitting multiple sclerosis.

Journal: Journal of the neurological sciences

Published: July 22, 2024

Relapse recovery in relapsing-remitting multiple sclerosis: An analysis of the CombiRx dataset.

Relapse recovery in relapsing-remitting multiple sclerosis: An analysis of the CombiRx dataset.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: October 13, 2023

Showing 1-12 of 46

Last Updated: 09/26/2026